Sanara MedTech (SMTI) PT Lowered to $40 at Cantor Fitzgerald, Overweight Rating Maintained May 20, 2022 06:04AM
Near to go Public on Nasdaq via Merger with KludeIn I Acquisition Corp. (INKA) May 19, 2022 07:33AM
Form 4 BGC Partners, Inc. For: May 17 Filed by: CANTOR FITZGERALD, L. P. May 18, 2022 09:06PM
Cantor Fitzgerald Reiterates Overweight Rating, $53 Price Target on Insmed (INSM) May 18, 2022 06:10PM
Form 4 NEWMARK GROUP, INC. For: May 17 Filed by: CANTOR FITZGERALD, L. P. May 18, 2022 05:27PM
View Older Stories

May 18, 2022 09:37AM Allakos Inc. (ALLK) PT Lowered to $10 at Cantor Fitzgerald, But BUY Rating Maintained, "Still Believe that the Market Opportunity for lirentelimab is Underappreciated"
May 18, 2022 06:17AM Cantor Fitzgerald Reiterates Overweight Rating, $7 Price Target on VolitionRX (VNRX), Has a "More Favorable View of the Company"
May 18, 2022 06:13AM Cantor Fitzgerald Reiterates Overweight Rating, $19 Price Target on Exagen (XGN) on Alivio Health Agreement
May 18, 2022 06:02AM Form SC 13D/A Satellogic Inc. Filed by: CANTOR FITZGERALD, L. P.
May 17, 2022 05:04PM Form 424B3 Cantor Fitzgerald Income
May 17, 2022 07:01AM Appreciate to Go Public Via Merger with PropTech Investment Corporation II (PTICU)
May 17, 2022 06:48AM Cantor Fitzgerald Reiterates Neutral Rating on TherapeuticsMD (TXMD)
May 17, 2022 06:13AM UPDATE: Aytu Biosciences (AYTU) PT Lowered to $5 at Cantor Fitzgerald, "Overweight" Rating Reiterated, Analyst Expects "Upwards Earnings Revisions Should Drive Shares Higher"
May 17, 2022 06:13AM Spero Therapeutics (SPRO) PT Slashed to $5 at Cantor Fitzgerald, Analyst Maintains "Overweight" Rating
May 16, 2022 05:52PM Form 13F-NT CANTOR FITZGERALD & CO. For: Mar 31
May 16, 2022 05:33PM Form 13F-HR CANTOR FITZGERALD, L. For: Mar 31
May 16, 2022 05:18PM Form 13F-NT CANTOR FITZGERALD SECURI For: Mar 31
May 16, 2022 05:02PM Form 13F-NT Cantor Fitzgerald Europe For: Mar 31
May 16, 2022 04:42PM Form 10-Q Cantor Fitzgerald Income For: Mar 31
May 16, 2022 03:43PM Form SC 13G Cartesian Growth Corp Filed by: CANTOR FITZGERALD SECURITIES
May 16, 2022 09:49AM Cantor Fitzgerald Reiterates Overweight Rating. $15 Price Target on ContraFect (CFRX), "Expect Upwards Earnings Revision to Move Share Higher"
May 16, 2022 06:49AM UPDATE: Benchmark Downgrades Shift Technologies Inc. (SFT) to Hold
May 16, 2022 05:27AM Lionheart Acquisition Corporation II (LCAPU) Enters Non-Binding Term Sheets for Forward Purchase Agreement and Committed Equity Facility with Cantor Fitzgerald
May 13, 2022 04:18PM Cantor Fitzgerald Assumes Poseida Therapeutics, Inc (PSTX) at Overweight
May 13, 2022 02:43PM Cantor Fitzgerald Assumes Harpoon Therapeutics (HARP) at Overweight
May 13, 2022 07:01AM CF Acquisition Corp. VI (CFVI) and Rumble File Amended Registration Statement for Proposed Merger
May 13, 2022 06:27AM Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight with $10 Price Target, Expects "Upwards Earnings Estimate Revisions and Multiple Expansion"
May 13, 2022 06:25AM Cantor Fitzgerald Reiterates Overweight Rating on Fortress Biotech (FBIO) on Q1 Report, "Risk-Diversification Remains Attractive "
May 13, 2022 06:19AM Cantor Fitzgerald Reiterates Overweight Rating on Checkpoint Therapeutics (CKPT) on Q1 Report
May 13, 2022 06:10AM Cantor Fitzgerald Reiterates Overweight Rating, $5 on PAVmed (PAVM), "Encourage Investors to Acquire PAVM Shares at Attractive Valuation"
May 12, 2022 09:44AM Cantor Fitzgerald Reiterates Overweight Rating, $18 Price Target on Aravive (ARAV), "Peak Sales Potential of AVB-500 Remains Underappreciated"
May 12, 2022 06:21AM Cantor Fitzgerald Reiterates Overweight Rating. $5 Price Target on Cidara Therapeutics (CDTX), "We Believe Street Under-appreciated Sales Potential of CDTX's Two Pipeline Assets"
May 12, 2022 05:55AM Cantor Fitzgerald Maintains ProQR Therapeutics N.V. (PRQR) at Overweight with $3.50 Price Target
May 11, 2022 06:09AM Form 13F-HR/A CANTOR FITZGERALD INVEST For: Mar 31
May 10, 2022 10:21AM Curaleaf (CURLF) PT Lowered to $14.60 at Cantor Fitzgerald
May 10, 2022 09:39AM 'Welcome Relief': 3 Analysts Discuss Pfizer's $11.6 Billion Deal to Acquire Biohaven (BHVN)
May 10, 2022 05:40AM Biotech Acquisition (BIOT) and Blade Therapeutics Announce Effectiveness of Registration Statement, Signs $75M Committed Equity Financing
May 9, 2022 08:31AM RedHill Biopharma (RDHL) Announces 10.57M ADS Direct Offering at $1.42/ADS
May 6, 2022 04:51PM Form 40-17G CANTOR FITZGERALD SUSTAI
May 6, 2022 05:45AM Cartesian Growth Corporation II (RENEU) Prices 20M Unit IPO at $10/unit
May 5, 2022 05:50PM Form 8-K Cantor Fitzgerald Income For: May 02
May 4, 2022 04:56PM Form 4 Cantor Fitzgerald Income For: May 02 Filed by: LUTNICK HOWARD W
May 4, 2022 06:19AM Cantor Fitzgerald Reiterates Overweight Rating on SeaSpine Holdings (SPNE) Following Q1 Report, Sees "Likely Share Price Appreciation"
May 3, 2022 05:32PM Form 424B3 Cantor Fitzgerald Income
May 3, 2022 09:01AM Pfizer (PFE) Sales Beat Estimates on Robust Covid Vaccine Sales; Analyst Weigh In on Results
May 3, 2022 06:57AM Cantor Fitzgerald Reiterates Overweight Rating, $85 Price Target on Cutera (CUTR)
Apr 29, 2022 05:51PM Form 10-K/A Cantor Fitzgerald Income For: Dec 31
Apr 29, 2022 03:25PM UPDATE: Cantor Fitzgerald Downgrades Emergent BioSolutions (EBS) to Neutral
Apr 29, 2022 05:54AM Sono Group (SEV) Prices 10M Share Follow-on Offering at $4/sh
Apr 29, 2022 05:52AM UPDATE: Cantor Fitzgerald Starts Roivant Sciences (ROIV) at Overweight
Apr 28, 2022 05:25PM Cantor Fitzgerald Reiterates Overweight Rating, $21 Price Target on SeaSpine Holdings (SPNE)
Apr 27, 2022 09:46AM Cantor Fitzgerald Reiterates Overweight Rating, $12 Price Target on Lucid Diagnostics Inc (LUCD) on BeiGene's RATIONALE 306 Trial Data, "Encourage Investors to Acquire LUCD Shares at an Attractive Ent
Apr 27, 2022 05:55AM Veru (VERU) and Opiant (OPNT) Top Cantor Fitzgerald's List of Largest Short Interest Increases
Apr 26, 2022 04:11PM Sono Group (SEV) Announces 10M Share Follow-on Offering
Apr 26, 2022 10:46AM Form SC 13G Arbor Rapha Capital Bioh Filed by: CANTOR FITZGERALD SECURITIES
View Older Stories